The CJEU’s decision in Royalty Pharma has provided much-anticipated guidance on supplementary protection certificates but has left a lot of uncertainty. Was this the best the CJEU could come up with? Beatriz San Martin of Arnold & Porter reports.
The exciting field of microbiome therapeutics offers many opportunities for ‘Big Pharma’ players that are staring over the exclusivity cliff, say Craig Thomson, Leena Contarino and Andrew Wells of HGF.
Foreign patents protecting COVID-19 treatments may stall efforts to protect citizens, says Mark Engelman of Hardwicke chambers.
The UK government’s indemnifying of ventilator manufacturers is a smart solution to potential licensing obstacles, says Andrew Pitts of Mewburn Ellis.
Pressure is building on IP owners to offer up access to technology that could help fight COVID-19. Rory O'Neill looks at some of the implications for the patent system.
New legislation has been enacted to help in the efforts to deal with the COVID-19 outbreak, as Daphne Lainson and Nancy Pei of Smart & Biggar report.
Jonathan Tietz, Jason Mock, and Kristel Schorr of Foley & Lardner offer their thoughts on patent procurement and licensing for COVID-19-related technologies.
Richard Fawcett, senior associate at Powell Gilbert, outlines why the UK patent system poses no obstacle to the UK government’s rallying call for ventilator production amid the COVID-19 pandemic.
The search for clarity goes on as Broad gears up for another set of legal challenges, as Claire Irvine, partner at HGF, explains.
Ahead of the Global IP Exchange Europe on March 9-11 in Berlin, the event’s organisers surveyed senior executives to find out their IP, patent, trademark, and brand protection investment priorities for the next 6-12 months.